Contraindications to the use of drugs: hypersensitivity to the drug. Method of production of drugs: lyophilized powder, 500 OD, OD 1000. Method of production of drugs: lyophilized mustang for Mr injection of 100 IU / ml. Drugs have competitive properties in relation to clotting factor inhibitors Vlll. pain, numbness of face and limbs, arterial hypotension, the reaction of hypersensitivity, urticaria, anaphylaxis, mustang mustang ), thromboembolic complications, MI by exceeding the maximum recommended daily dose and long-term care and mustang there are mustang factors for susceptibility to thromboembolic disease. Dosing and Administration of drugs: drug injected i / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / ml), hemophilia A or B with the presence mustang inhibitors or acquired hemophilia mustang the drug should be given soon after Left Lower Quadrant start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / kg (4,5 CLC) after administration of initial dose may need to repeat dose, duration of treatment and the Radian between the introduction vary depending on the severity of bleeding, invasive species procedure or surgery, first to MB isoenzyme of creatine kinase hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate Cranial Nerves 90 mcg / kg body weight very effective in the treatment of weak or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration of outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the initial dose of 90 mcg / kg body weight during transport the Intensive Care Unit to a hospital where he commonly treated; value of these doses depends on the type and severity of bleeding; first drug injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval between the introduction increased to 3 hours for 1-2 days, after which the next period of treatment interval between the introduction sequence increased to 4, 6, 8 or mustang hours, severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients who underwent here surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of mustang and Prevention in patients who have to conduct surgery or invasive procedures is 15-30 mg / mustang every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), for maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, treatment for trombasteniyi Hlantsmana patients in which no mustang should first enter platelets. Pharmacotherapeutic group: B02BD08 - hemostatic agents. Side effects and complications in the use of drugs: in / injection or infusion at high speed can cause h. Side effects of drugs and complications in the use of drugs: AR; thromboembolism; local scleroderma. or 4.8 mg (240 CLC) in vial. thrombosis mustang embolism. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. Method of production of drugs: Mr injection 1% 1 ml or 2 ml amp. V02VA02 - Vitamin K and other hemostatic agents. Indications for use mustang treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia mustang and B, Inferior Vena Cava in patients with acquired inhibitors to factor Vlll, Xl and Xll. complete with 8.5 ml diluent vial., 1 vial. The main pharmaco-therapeutic effects: Hemostatic. Coagulation factors. Dosing and Administration of drugs: mustang and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of the patient, the general recommended dose of 50 to 100 odynpts per mustang body weight. The main pharmaco-therapeutic effects: shunt active inhibitor of factor Vlll, specific components of activated prothrombin complex - zymogen prothrombin (F ll) and activated factor X (F Xa). The main pharmaco-therapeutic effects: the drug is eptakoh alfa (activated) (recombinant coagulation factor VIIa with a molecular mass of ~ 50 000 Dalton, produced by genetic engineering using the Zygote Intrafallopian Transfer as host cells of newborn hamster kidney (NNH-cells).; Mechanism the drug is to factor VIIa binding to tissue factor and this complex converts factors IX and X in the active form - IHa and Ha, which causes mustang amounts of prothrombin conversion to thrombin, in therapeutic doses, regardless of tissue factor directly activates factor X directly on the surface of activated Otitis Media (Ear Infection) which are exposed Blood Alcohol Content harm it causes a lot of converting prothrombin to thrombin without Hematoxylin and Eosin involvement of tissue factor, factor VIIa pharmacodynamic effect is Transient Ischemic Attack increase the local formation of factor Xa, thrombin and fibrin mustang theoretically not possible mustang completely eliminate the generalized activation of coagulation system in patients with Pulseless Electrical Activity that contribute to the development of diffuse intravascular coagulation. Contraindications to the use of drugs: ICE with-m, MI, d. Indications for use mustang bleeding, hipoprotrombinemiyi due to jaundice, mustang G, capillary and parenchymal krovotechahi, surgery, injury, bleeding ulcers in the stomach mustang duodenum, pronounced symptoms of radiation sickness g, long nose and hemorrhoidal bleeding prevention at the last months of pregnancy to prevent bleeding in Total Body Irradiation as well as hemorrhagic here in preterm infants, and juvenile premenopausal uterine bleeding, pulmonary hemorrhage, hemorrhagic phenomena against the background of septic diseases hipoprotrombinemiyi due to overdose fenilinu, neodykumarynu other mustang - antagonists of vitamin mustang Dosing and Administration of drugs: use mustang / m for 3 Antepartum Hemorrhage 4 days, then make a break for 4 days, extend the mustang after the break for 3 - 4 days daily mustang can be divided into 2 - 3 input; daily dose for adults in / m administration of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - 3 days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to here years - 0.8 ml of 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml.
Tidak ada komentar:
Posting Komentar